Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2020.2950
Abstract: Key Points Question Is treatment with a fingolimod dose of 0.5 mg or 0.25 mg superior to glatiramer acetate, 20 mg, in reducing relapse activity over 12 months in adult participants aged 18 to 65… read more here.
Keywords: relapsing remitting; treatment; fingolimod; multiple sclerosis ... See more keywords
Fingolimod attenuates ovalbumin‐induced airway inflammation via inhibiting MAPK/ERK signaling in mice
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Biochemical and Molecular Toxicology"
DOI: 10.1002/jbt.23266
Abstract: The current study was designed to investigate the potential anti‐inflammatory and antioxidant effects of fingolimod against Ovalbumin (Ova)‐induced allergic airway inflammation compared to dexamethasone. Fingolimod was given (0.5 mg/kg/day, p.o.) for sensitized mice 1 h before Ova… read more here.
Keywords: inflammation; ova induced; fingolimod; airway inflammation ... See more keywords
Clinical exacerbation of SARS‐CoV2 infection after fingolimod withdrawal
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Virology"
DOI: 10.1002/jmv.26279
Abstract: The role of disease‐modifying therapies in patients with autoimmune disorders during severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) infection is controversial. Immunocompromised patients could have a more severe coronavirus disease‐2019 (COVID‐19) due to the absence… read more here.
Keywords: cov2 infection; sars cov2; fingolimod withdrawal; fingolimod ... See more keywords
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02693-7
Abstract: Immune checkpoint inhibitors (ICIs) are emerging as the new standard of care for treating various metastatic cancers. It is known that effective anti-tumor immune responses are associated with a stronger presence of tumor-infiltrating lymphocytes (TILs)… read more here.
Keywords: infiltrating lymphocytes; fingolimod; tumor infiltrating; cancer ... See more keywords
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09195-2
Abstract: BackgroundIt has been described that treating relapsing–remitting multiple sclerosis (RRMS) patients with alemtuzumab following fingolimod could be less effective due to the different dynamics of lymphocyte repopulation. Effectiveness and safety of alemtuzumab compared to rituximab… read more here.
Keywords: rituximab fingolimod; alemtuzumab rituximab; fingolimod withdrawal; fingolimod ... See more keywords
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
Sign Up to like & getrecommendations! Published in 2020 at "Neurological Sciences"
DOI: 10.1007/s10072-020-04726-6
Abstract: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. Retrospective,… read more here.
Keywords: effectiveness safety; relapsing remitting; safety; fingolimod ... See more keywords
Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Neurobiology"
DOI: 10.1007/s12035-020-01908-3
Abstract: The imbalance in sphingolipid signaling may be critically linked to the upstream events in the neurodegenerative cascade of Alzheimer’s disease (AD). We analyzed the influence of mutant (V717I) amyloid β precursor protein (AβPP) transgene on… read more here.
Keywords: animal model; metabolism; alzheimer disease; enzymes ceramide ... See more keywords
Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Neurobiology"
DOI: 10.1007/s12035-021-02613-5
Abstract: Therapeutic strategies for Alzheimer’s disease (AD) have largely focused on the regulation of amyloid pathology while those targeting tau pathology, and inflammatory mechanisms are less explored. In this regard, drugs with multimodal and concurrent targeting… read more here.
Keywords: fingolimod; memory; model; pathology ... See more keywords
Fingolimod Immune Effects Beyond Its Sequestration Ability
Sign Up to like & getrecommendations! Published in 2019 at "Neurology and Therapy"
DOI: 10.1007/s40120-019-00162-7
Abstract: Fingolimod is the first orally administered drug approved for the treatment of relapsing–remitting multiple sclerosis (MS). This drug, modulating sphingosine receptors, regulates the trafficking of lymphocytes between primary and secondary lymphoid organs, trapping naïve T… read more here.
Keywords: beyond sequestration; fingolimod immune; memory cells; fingolimod ... See more keywords
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
Sign Up to like & getrecommendations! Published in 2017 at "CNS Drugs"
DOI: 10.1007/s40263-017-0415-2
Abstract: Brain atrophy occurs at a faster rate in patients with multiple sclerosis (MS) than in healthy individuals. In three randomized, controlled, phase III trials, fingolimod reduced the annual rate of brain volume loss (BVL) in… read more here.
Keywords: fingolimod; patients multiple; rate; brain volume ... See more keywords
Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod
Sign Up to like & getrecommendations! Published in 2020 at "IDCases"
DOI: 10.1016/j.idcr.2020.e00961
Abstract: Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS), with an estimated 2.3 million people being affected globally, and is a major cause of permanent disability. About 90 %… read more here.
Keywords: disseminated cryptococcal; multiple sclerosis; increased risk; fingolimod ... See more keywords